Viewing Study NCT04111705

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 3:29 AM
Ignite Modification Date: 2026-03-08 @ 3:39 AM
Study NCT ID: NCT04111705
Status: COMPLETED
Last Update Posted: 2025-04-01
First Post: 2019-08-30
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Lorlatinib After Failure of First-line Second-generation ALK Kinase Inhibitor in Patients With Advanced ALK-positive Non-small Cell Lung Cancer
Sponsor: Intergroupe Francophone de Cancerologie Thoracique
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Non Small Cell Lung Cancer Metastatic View
Keywords:

Keywords

Keyword Brief Keyword Text View
None IFCT View
None ORAKLE View
None NSCLC View
None ALK-positive View
None monotherapy View